دورية أكاديمية
Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition
| العنوان: | Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition |
|---|---|
| المؤلفون: | Skendros P., Papagoras C., Lefaki I., Giatromanolaki A., Kotsianidis I., Speletas M., Bocly V., Theodorou I., Dalla V., Ritis K. |
| المصدر: | British Journal of Dermatology ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-84997113282&doi=10.1111%2fbjd.14685&partnerID=40&md5=9d1d4e99a2cf13479ebd6b3fc7a4feeaTest |
| سنة النشر: | 2017 |
| المجموعة: | University of Thessaly Institutional Repository / Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας |
| مصطلحات موضوعية: | anakinra, antibiotic agent, canakinumab, fresh frozen plasma, glucocorticoid, hydroxyurea, imatinib, interleukin 1beta, methylprednisolone, prednisolone, dermatological agent, interleukin 1 receptor blocking agent, monoclonal antibody, adult, Article, case report, Caucasian, cholestasis, cholestatic hepatitis, diabetes mellitus, drug dose reduction, drug efficacy, drug substitution, drug tolerability, drug withdrawal, echography, eosinophilia, erythema, erythroderma, fever |
| الوصف: | Generalized pustular psoriasis (GPP) is a severe type of psoriasis accompanied by systemic and often life-threatening manifestations. The efficacy of the interleukin (IL)-1 antagonist anakinra in cases of GPP underscores the role of IL-1 in disease pathogenesis. We present a case of a middle-aged man who developed an abrupt and severe form of GPP with severe eosinophilia and cholestatic hepatitis. The patient received salvage treatment with a combination of glucocorticoids, hydroxyurea and imatinib, while administration of the IL-1 inhibitor anakinra resulted in remission of hepatitis and a significant skin improvement. However, due to persistent hypersensitivity skin reactions, anakinra was withdrawn and replaced with the anti-IL-1β antagonist canakinumab. As a result of canakinumab, the patient's skin completely cleared, while no systemic manifestations recurred. After 1 year of continuous canakinumab therapy, the patient remained virtually free of symptoms, while the drug was well tolerated. © 2016 British Association of Dermatologists |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 00070963 |
| العلاقة: | http://hdl.handle.net/11615/79086Test |
| DOI: | 10.1111/bjd.14685 |
| الإتاحة: | https://doi.org/10.1111/bjd.14685Test http://hdl.handle.net/11615/79086Test |
| رقم الانضمام: | edsbas.6F8AC2F0 |
| قاعدة البيانات: | BASE |
| تدمد: | 00070963 |
|---|---|
| DOI: | 10.1111/bjd.14685 |